International Severe Asthma Registry_Hong Kong

International Severe Asthma Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07524543

Acronym

ISAR

Enrollment

500

Registered

2026-04-13

Start date

2025-11-01

Completion date

2036-12-31

Last updated

2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma

Brief summary

To ensure the care of people with severe asthma continues to improve, it is essential we have detailed information on the health and treatment of as many people with the condition as possible. The purpose of the registry is to gather this information and track the progress of patients and how well they are responding to treatment. Medical research using data from the registry will provide a better understanding of asthma and help to develop and improve the care and treatment for patients with asthma. Detailed protocol can be referred to the reference in this trial registration (International severe asthma registry \[ISAR\]: protocol for a global registry).

Detailed description

This registry is a multi-country, multicentre, observational initiative which will retrospectively and prospectively collect data regarding severe asthma patients. The key feature of the International Severe Asthma Registry will be a standardised annualised recording of: A key set of severe asthma related data points Selected enhanced data points for optional additional data collection Standardised coding for data point variables and Standardised response options. Asthma patients in Hong Kong will be contributing to this dataset/registry. All clinical information will be anonymised in the dataset to protect patient confidentiality.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

Patient with severe asthma with age 18 or over will be recruited.

Exclusion criteria

Patients who cannot provide written consent

Design outcomes

Primary

Measure	Time frame	Description
Asthma exacerbations	Every year up to 10 years	Number of asthma exacerbations per year

Secondary

Measure	Time frame	Description
Change of medications	every year up to 10 years	Change of asthma medications

Countries

Hong Kong

Contacts

CONTACTWai San Fanny Ko, MD

fannyko@cuhk.edu.hk+852 35053133

CONTACTDavid Shu Cheong Hui, MD

dschui@cuhk.edu.hk+852 35053133

Outcome results